Background:?We report the case of a 58-year-old hypertensive patient under treatment who presented with a ventricular tachycardia unveiling an obstructive cardiomyopathy complicated with an apical aneurysm. Aim: Highlight the rarity of the case and the difficulty of management. Case Presentation: This patient was transferred from Regional Hospital of Ziguinchor in southern Senegal for a brutal dizzy spell without loss of consciousness. The electrocardiogram showed a wide monomorphic QRS complex regular tachycardia with a rate of 215 beats/min. An external electrical cardioversion at 300 joules was applied which led to the recovery of a sinus rhythm on the electrocardiogram. The Doppler echocardiography showed an asymetricalmedio-ventricular hypertrophy with a maximum left intraventricular gradient at 10 mm Hg at rest. The coronarography via the radial artery was normal. The evolution was labeled with a recurrence of the ventricular tachycardia. The patient was then put on amiodarone 200 mg, beta-blocker (bisoprolol 10 mg) and anti-vitamin K (acenocoumarol 4 mg). Facing rhythmic instability, an implantable automatic defibrillator was fitted. No complication has been reported after one year of evolution. Conclusion: HCM with medio ventricular obstruction and apical aneurysm complicated with ventricular arrhythmias is a rare entity. Its management is difficult and controversial.
References
[1]
Maron, B.J., Gardin, J.M., Flack, J.M., Gidding, S.S., Kurosaki, T.T. and Bild, D.E. (1995) Prevalence of Hypertrophic Cardiomyopathy in a General Population of Young Adults: Echocardiographic Analysis of 4111 Subjects in the CARDIA Study Coronary Artery Risk Development in (Young) Adults. Circulation, 92, 785-789.
https://doi.org/10.1161/01.CIR.92.4.785
[2]
Maron, B.J., Yeates, L. and Semsarian, C. (2011) Clinical Challenges of Genotype Positive (+)—Phenotype Negative (-) Family Members in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 107, 604-608.
https://doi.org/10.1016/j.amjcard.2010.10.022
[3]
Maron, B.J. and Semsarian, C. (2010) Emergence of Gene Mutation Carriers and the Expanding Disease Spectrum of Hypertrophic Cardiomyopathy. European Heart Journal, 31, 1551-1553. https://doi.org/10.1093/eurheartj/ehq111
[4]
Rowin, E.J., Maron, B.J., Haas, T.S., Garberich, R.F., Wang, W., Link, M.S., et al. (2017) Hypertrophic Cardiomyopathy with Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management. Journal of the American College of Cardiology, 69, 761-773. https://doi.org/10.1016/j.jacc.2016.11.063
Olszewski, R., Timperley, J., Szmigielski, C., Monaghan, M., Nihoyannopoulos, P., Senior, R., et al. (2007) The Clinical Applications of Contrast Echocardiography. European Journal of Echocardiography, 8, S13-S23.
https://doi.org/10.1016/j.euje.2007.03.021
[7]
Minami, Y., Kajimoto, K., Terajima, Y., Yashiro, B., Okayama, D., Haruki, S., et al. (2011) Clinical Implications of Midventricular Obstruction in Patients with Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 57, 2346-2355. https://doi.org/10.1016/j.jacc.2011.02.033
[8]
Efthimiadis, G.K., Pagourelias, E.D., Parcharidou, D., Gossios, T., Kamperidis, V., Theofilogiannakos, E.K., et al. (2013) Clinical Characteristics and Natural History of Hypertrophic Cardiomyopathy with Midventricular Obstruction. Circulation Journal, 77, 2366-2374. https://doi.org/10.1253/circj.CJ-12-1561
[9]
Maron, M.S., Maron, B.J., Harrigan, C., Buros, J., Gibson, C.M., Olivotto, I., et al. (2009) Hypertrophic Cardiomyopathy Phenotype Revisited after 50 Years with Cardiovascular Magnetic Resonance. Journal of the American College of Cardiology, 54, 220-228. https://doi.org/10.1016/j.jacc.2009.05.006
[10]
Olivotto, I., Maron, M.S., Autore, C., Lesser, J.R., Rega, L., Casolo, G., et al. (2008) Assessment and Significance of Left Ventricular Mass by Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 52, 559-566. https://doi.org/10.1016/j.jacc.2008.04.047
Elliott, P.M., Anastasakis, A., Borger, M.A., Borggrefe, M., Cecchi, F., Charron, P., et al. (2014) 2014 ESC Guidelines on Diagnosis and Management of Hypertrophic Cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). European Heart Journal, 35, 2733-2779. https://doi.org/10.1093/eurheartj/ehu284
[14]
Dubourg, O., Charron, P., Desnos, M., et al. (2011) Cardiomyopathie Hypertrophique: Protocole national de diagnostic et de soins pour les maladies rares. HAS.
http://www.has-sante.fr/portail/jcms/c_1100272/fr/ald-n5-cardiomyopathie-hypertrophique
[15]
Gersh, B.J., Maron, B.J., Bonow, R.O., Dearani, J.A., Fifer, M.A., Link, M.S., et al. (2011) 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American. Circulation, 124, e783-e831.
https://doi.org/10.1161/CIR.0b013e318223e2bd